| Basics |
Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.
|
| IPO Date: |
April 20, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$163.06M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.26 | 3.14%
|
| Avg Daily Range (30 D): |
$0.09 | 2.82%
|
| Avg Daily Range (90 D): |
$0.09 | 2.94%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
.33M |
| Avg Daily Volume (90 D): |
.33M |
| Trade Size |
| Avg Trade Size (Sh.): |
119 |
| Avg Trade Size (Sh.) (30 D): |
107 |
| Avg Trade Size (Sh.) (90 D): |
107 |
| Institutional Trades |
| Total Inst.Trades: |
3,679 |
| Avg Inst. Trade: |
$2.05M |
| Avg Inst. Trade (30 D): |
$3.09M |
| Avg Inst. Trade (90 D): |
$1.84M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.6M |
| Avg Closing Trade (30 D): |
$.59M |
| Avg Closing Trade (90 D): |
$.59M |
| Avg Closing Volume: |
76.93K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$.06
|
$.41
|
|
Diluted EPS
|
|
$.06
|
$.41
|
|
Revenue
|
$
|
$ 46.01M
|
$ 80.54M
|
|
Gross Profit
|
$
|
$ 35.45M
|
$ 51.45M
|
|
Net Income / Loss
|
$
|
$ 2.97M
|
$ 20.32M
|
|
Operating Income / Loss
|
$
|
$ 3.98M
|
$ 22.08M
|
|
Cost of Revenue
|
$
|
$ 10.56M
|
$ 29.1M
|
|
Net Cash Flow
|
$
|
$ -6.19M
|
$ .11M
|
|
PE Ratio
|
|
|
|
|
|
|
